Merofen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Merofen

Meropenem: A Quick Overview of Its Identity and Role

Property Description
Active Ingredient Meropenem
Form Powder for solution for injection/infusion
Pharmacological Class Carbapenem Antibiotic
General Purpose Treatment of severe bacterial infections
Origin Synthetic (manufactured)

Meropenem is the established International Nonproprietary Name (INN) for a powerful, broad-spectrum antibiotic used to treat serious bacterial infections. It is often marketed under brand names like Merofen or Meronem. Meropenem is a highly regarded medication, recognized for its effectiveness against a wide range of bacteria, including those that have developed resistance to common drugs.

What Type of Medicine is Meropenem and Where Does it Come From?

Meropenem is a synthetic substance belonging to the specialized carbapenem pharmacological class, a group of beta-lactam antibiotics that are highly resilient to bacterial defenses. This classification grants Meropenem a broad spectrum of activity against difficult-to-treat organisms.

Because of its critical nature, the drug is formulated as a sterile powder and is administered exclusively via intravenous (IV) injection or infusion directly into the bloodstream. This intravenous-only form signifies its role in managing severe, systemic diseases where immediate, high drug concentrations are required.

Meropenem's Primary Therapeutic Purpose (General Scope)

Meropenem's primary therapeutic purpose is to stop the propagation of and eliminate harmful bacteria in patients facing severe systemic infections. It serves a crucial function in cases of suspected sepsis or complicated infections that might involve multi-drug resistant (MDR) organisms. Meropenem is classified as an essential medicine, reflecting its importance in emergency and intensive care settings.

Regulatory References

  1. Meropenem on WHO Electronic Essential Medicines List
  2. WHO Model List of Essential Medicines

What side effects are possible with Merofen?

Possible Side Effects and Safety Information for Merofen (Meropenem)

The official safety profile of Meropenem is established through regulatory classification, detailing potential adverse reactions across multiple physiological systems. These documented effects are categorized by frequency, allowing for a structured understanding of expected risks.

Frequency-Classified Adverse Reactions

The documented adverse effects are grouped by the likelihood of occurrence, as defined in regulatory labeling (e.g., EMA Summary of Product Characteristics, FDA Prescribing Information):

Classification Examples of Documented Effects
Very Common Positive direct or indirect Coombs test (a laboratory finding).
Common Headache, diarrhea, nausea, vomiting, abdominal pain, rash, pruritis, and transient increases in liver enzymes (e.g., transaminases).
Uncommon Leukopenia, neutropenia, thrombocytopenia, paresthesia, hypotension, and increased blood creatinine/urea.
Rare Seizures (convulsions) and delirium.

Serious Adverse Reactions and Safety Constraints

The regulatory profile identifies specific Serious Adverse Reactions (SARs) that require attention, including anaphylaxis and severe hypersensitivity, Pseudomembranous colitis (severe diarrhea), and severe cutaneous adverse reactions like Stevens-Johnson syndrome (SJS).

Safety is also framed by explicit restrictions: Meropenem is contraindicated in individuals with known hypersensitivity to the drug, to any other carbapenem antibacterial agent, or to any other type of beta-lactam agent (e.g., penicillins) due to the risk of severe reactions.

Population-specific notes are included for certain patient groups. For instance, individuals with pre-existing Central Nervous System (CNS) disorders are noted to have an increased risk of seizures. Additionally, renal impairment reduces the drug's clearance, which is a key safety consideration detailed in official regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the overdose profile for Meropenem primarily by documenting potential manifestations and the required emergency response.

Element Official Regulatory Statement
Documented Overdose Presentations Adverse reactions following overdose are generally mild and consistent with the established adverse reaction profile, resolving upon drug withdrawal or dose reduction.
Physiological Systems Affected The Central Nervous System (CNS) is the system implicated in serious dose-related toxicity, manifesting as Seizures (Convulsions).
Dose-Related Factors Relative overdose is possible in patients with renal impairment if the dosage is not appropriately adjusted based on regulatory guidelines.
Emergency-Response Treatment for accidental overdosage must be symptomatic and supportive.
Urgent Help Required In the event of suspected accidental overdosage, contact your doctor or nearest hospital straight away for immediate clinical assessment.

Official Overdose Statements

  • The most significant dose-related severe outcome is the potential for seizures (convulsions), which necessitates urgent medical evaluation.
  • Meropenem is removed from the circulation by haemodialysis and haemofiltration, although the clinical usefulness of this procedure for managing overdose is not formally established.
  • There is no specific antidote known for Meropenem overdosage.
  • Regulatory documents note no experience with the use of Meropenem in pediatric patients with renal impairment.

Connection to the Overall Overdose Profile

Regulatory documents define the Meropenem overdose profile by focusing on the need for immediate clinical intervention and symptomatic and supportive treatment due to the lack of a known antidote. The profile highlights seizures as the primary dose-related severe manifestation that requires management. This structure confirms the drug's removability via dialysis and establishes the need for careful risk assessment, particularly in the renally impaired population.

Therapeutic Uses of Merofen

Meropenem (Merofen is a brand name) is a carbapenem antibiotic, a class of medication applied across domains where additional symptomatic support is needed for serious bacterial infections. The drug is commonly used across conditions presenting with acute episodes of systemic infection.

Meropenem is applied in addressing clinical scenarios involving infection. This includes complicated skin and soft tissue infections, complicated intra-abdominal infections, acute bacterial meningitis, severe pneumonia (including hospital-associated types), complicated urinary tract infections, and infections in patients with cystic fibrosis. It may be part of symptomatic management for febrile neutropenic patients where a bacterial infection is suspected.

Meropenem supports the therapeutic strategy, which is an action applied in addressing symptoms related to systemic imbalance and symptoms that create noticeable physiological strain. This supportive relief contributes to easing the overall symptom load during periods of heightened symptoms.

“It supports the patient during difficult episodes by easing distress during episodes of heightened discomfort.”

Quick Fact: Relief for symptoms that create noticeable physiological strain.

Eligibility and Restrictions for Use

Official Eligibility Profile

Meropenem (Merofen) eligibility is defined by regulatory bodies based on absolute contraindications and strict population restrictions. The medicine must not be used by individuals with a known hypersensitivity to the active substance, to any other carbapenem antibiotic, or who have a history of a severe allergic reaction (such as anaphylaxis) to any beta-lactam antibiotic, including penicillins [FDA Prescribing Information].

Use is allowed in adults, adolescents, and pediatric patients 3 months of age and older. Use is not recommended for children under 3 months as safety and efficacy have not been established [UK SmPC].

Eligibility is conditional on patient status for several groups. In adults and adolescents with renal impairment, use is restricted and requires regulatory dose adjustment when Creatinine Clearance is leq 50 mL/min. Patients with certain Central Nervous System (CNS) disorders, such as a history of seizures, require caution [FDA Prescribing Information]. Use is also not recommended during pregnancy or lactation unless the clinical benefit strictly justifies the potential risk, as human safety data is not established in these states [NZ Data Sheet / Reg. Info].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Official Regulatory Documentation Statement
Medicinal product categories with documented interactions Anticonvulsants (Valproic acid derivatives), Uricosuric agents (Probenecid), Oral Anticoagulants (e.g., Warfarin).
Mechanistic basis of interactions Inhibition of Meropenem renal tubular secretion by Probenecid; Reduction of Valproate serum concentration by Meropenem; Enhancement of Anticoagulant effect.
Interaction-related restrictions Contraindicated combination with valproic acid derivatives. Not recommended for co-administration with Probenecid.

Interaction classifications

Category Official Regulatory Documentation Statement
Interaction severity classification Contraindication (with valproate); Not Recommended (with probenecid); Use with Caution/Monitoring Advised (with oral anticoagulants).
Regulatory basis Interaction information is based on FDA Prescribing Information and European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).
Interaction-context constraints The valproate interaction carries the specific constraint of potentially resulting in loss of seizure control.

Resulting interaction structure

Official regulatory documentation establishes that co-administration with Valproic Acid and its derivatives is defined as a highly significant interaction or contraindication. Meropenem is documented to cause a rapid and substantial reduction in valproate serum concentrations, a pharmacokinetic effect which creates a substantial risk of breakthrough seizures. Co-administration with Probenecid is also not recommended because this substance inhibits the renal tubular secretion of meropenem, thereby increasing the antibiotic's plasma exposure, including its AUC and peak concentration. Furthermore, an interaction with Oral Anticoagulants may enhance their anticoagulant effect, and official prescribing information advises monitoring the patient's coagulation metrics. Regulatory labels do not document specific interaction concerns with food, alcohol, herbal products, or mandatory dose separation requirements for administration.

Mechanism of Action

How Merofen Works

Inhibition of Bacterial Cell Wall Synthesis

Merofen's primary mechanism involves the inhibition of peptidoglycan synthesis, the process required to build and maintain the structural integrity of the bacterial cell wall. The drug achieves this by binding irreversibly to key bacterial enzymes, the Penicillin-Binding Proteins (PBPs), particularly PBP 2 and PBP 3, thereby blocking the necessary cross-linking reactions. This action ultimately leads to failure of structural rigidity, resulting in bacterial cell lysis and death (a bactericidal effect), a consequence of the resulting osmotic imbalance.


Stability Against beta-Lactamase Enzymes

The drug is designed with structural features that provide enhanced stability against breakdown by most common bacterial defense enzymes, the beta-lactamases. These enzymes typically inactivate beta-lactam antibiotics by hydrolyzing the beta-lactam ring. Merofen's resistance to this enzymatic degradation ensures that the intact drug molecule persists in its active form to engage its PBP targets, which enables the molecule to engage its target PBPs in the presence of beta-lactamase enzymes.

Dosage and Administration Information

How to Use Meropenem (Merofen) — Administration Guidelines

The administration of Meropenem focuses on controlled, intravenous delivery of the sterile powder for solution. All usage patterns, including dose and timing, are defined based on the type of infection being addressed.


Administration Scope

Instruction Category Guideline
Route of administration Strictly Intravenous (IV) Infusion or Intravenous (IV) Bolus Injection.
Dosing schedule (Adults) Standard unit doses range from 500 mg to 2 grams per administration. The 2-gram dose is generally reserved for severe infections, such as meningitis.
Frequency and Timing The standard dosing interval is every 8 hours (q8h). Treatment courses typically last 7 to 14 days.
Preparation requirements The single-dose sterile powder must be reconstituted and diluted with compatible intravenous fluids, such as 0.9% Sodium Chloride, prior to administration.
Age-group administration rules Dosing for pediatric patients weighing less than 50 kg is determined on a weight-based (mg/kg) schedule. For adults with renal impairment (CrCl le 50 mL/min), standard protocols require dose reduction and/or an extended interval to 12 or 24 hours.
Special procedural conditions The medicine must be given as an IV infusion over 15 to 30 minutes. Doses up to 1 gram may be administered as an IV bolus over 3 to 5 minutes.

Procedural Structure

The administration guidelines define a precise procedural structure for the use of Meropenem. This structure mandates intravenous delivery in a supervised setting, establishing a uniform frequency of every 8 hours for normal function. Furthermore, the instructions detail the dose adjustments necessary for patients with impaired kidney function and provide specific weight-based rules for pediatric use, standardizing its application.

Recent Clinical Evidence

Research evidence / Overview of studies for Meropenem


Evidence for Use in Complicated Intra-Abdominal Infections (cIAI)

The evidence base for Meropenem was evaluated in conditions characterized by complicated infections within the abdomen, such as those involving perforated organs or abscesses. This research comes primarily from short-term Randomized Controlled Trials (RCTs) and comparative studies against other antibiotics. These studies have primarily monitored short-term outcomes related to clinical success rates and the ability to clear specific harmful bacteria (known as microbiological eradication). Findings reported measurements of clinical success rates in the studied groups which described patterns comparable to those observed in patients receiving comparator antibiotics. Studies reported microbiological success rates, indicating the elimination of targeted pathogens, as observed in some studies during the defined time intervals.

Evidence for Use in Bacterial Meningitis

The research evidence for Meropenem was evaluated in conditions characterized by bacterial meningitis, and includes RCTs and registry-based analyses. Key research has explored outcomes primarily in pediatric patients ge 3 months of age. Comparative trials involving these younger populations reported patterns of clinical success rates and microbiological eradication that described patterns comparable to those observed with established alternative treatments. The body of evidence is less extensive for adult patients, and clinical studies rarely extend follow-up past the short-term recovery phase to characterize very long-term functional or neurological outcomes.

Evidence for Use in Complicated Skin and Soft Tissue Infections (cSSTIs)

The evidence base for Meropenem in deep, serious complicated skin and soft tissue infections (cSSTIs) was evaluated in RCTs and comparative trials. These studies monitored outcomes such as clinical success rates and microbiological clearance for the bacteria causing the infection. Regulatory-cited trials reported measurements of clinical response rates that were consistent across the studied groups, describing similar patterns to the chosen comparator drugs over the short term. The research also reported patterns related to microbiological eradication for the target pathogens observed in the study populations.

Research Gaps and Areas of Uncertainty

This summary highlights several areas where the research evidence is limited or requires further study. Follow-up durations were limited; the core clinical trials typically focus on the short-term course of infection and do not provide extensive data on long-term outcomes. Data for certain groups remain insufficient: While Meropenem was studied for children ge 3 months of age, research is very limited or absent for younger pediatric patients and other specific vulnerable populations. The evidence focuses on group patterns and does not determine whether an individual will respond similarly or if the infection will never recur.

Key Studies & References

  1. Meropenem Injection IP MERONEM - Pfizer (US Labeling)
  2. NG240 Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management: Evidence review D2 (NICE Guideline)

Frequently Asked Questions (FAQ)

Common questions about Merofen (FAQ)

Q: What is the main difference between Merofen and other similar drugs?

A: Merofen is classified as a carbapenem antibiotic. Official documents emphasize its structural stability, which allows it to resist breakdown by bacterial defense enzymes called beta-lactamases. This resistance is a key characteristic in its class that allows it to remain active against a broad range of bacteria, as described in its official documents.

Q: How quickly does Merofen start working after I take it?

A: Merofen's administration method—intravenous (IV) injection or infusion—is described in official documents as allowing it to rapidly achieve effective concentrations in the bloodstream. Furthermore, regulatory research indicates that the drug has a short half-life (elimination rate), meaning the body processes the medication relatively quickly.

Q: Is it okay to drive or operate machinery while taking Merofen?

A: Regulatory warnings mention potential central nervous system (CNS) side effects like headache, tingling (paresthesia), and, rarely, seizures or delirium. Official guidance advises caution regarding activities requiring mental alertness, such as driving or operating heavy machinery, until the individual understands the potential effects.

Q: Can older adults safely use Merofen?

A: Use is authorized for adults. Official guidelines require specific considerations if the patient has reduced kidney function (creatinine clearance le 50 mL/min), which is common in older adults. If renal impairment is present, the standard dosage schedule must be formally adjusted or the interval between doses extended, a safety measure detailed in regulatory prescribing information.

Q: How long does Merofen stay in your system after you stop taking it?

A: Merofen is rapidly eliminated from the body, primarily through the kidneys. According to regulatory data on pharmacokinetics, the drug's elimination half-life is typically about one hour in adults with normal kidney function. Approximately 70% of the drug is generally recovered in the urine within 12 hours of administration.

Q: Can Merofen be taken with or without food?

A: This question is not applicable for Merofen. The medicine is formulated only as a powder for injection and is administered strictly intravenously. It is not an oral medicine that is taken by mouth with food.

Q: Why is alcohol consumption generally discouraged while on Merofen?

A: While official regulatory documents do not list a direct chemical interaction between Merofen and alcohol, alcohol consumption may potentially potentiate central nervous system (CNS) side effects. This is a general caution associated with many drugs that affect CNS function or cause drowsiness.

Q: Can Merofen be used during pregnancy or while breastfeeding?

A: Official regulatory documents indicate that use is generally not recommended during pregnancy or lactation. The decision for use is reserved for situations where the clinical benefit is deemed to strictly justify the potential risk, as human safety data in these states are limited or not established.

Q: What is the common reason for stopping Merofen treatment early?

A: Merofen treatment is generally administered for a full course and is only stopped early if a serious or life-threatening adverse reaction occurs. These documented reasons include severe allergic reactions (such as anaphylaxis), severe skin conditions (like Stevens-Johnson syndrome), or severe inflammation of the bowel (Pseudomembranous colitis).

Q: Can Merofen be crushed or split if the tablets are large?

A: This question is not applicable, as Merofen is not available in a tablet form that can be crushed or split. It is supplied only as a sterile powder for solution that must be prepared and administered intravenously.

Q: What happens if I miss a scheduled time to take Merofen?

A: Merofen is typically given in a supervised clinical setting, where missed doses are rare. Official protocol is that a missed dose is to be immediately reported to the prescribing healthcare team. Patients are generally directed not to attempt to take extra doses to make up for a missed one.

Q: Can Merofen cause difficulty sleeping?

A: Official safety data lists 'trouble sleeping' (insomnia) and 'unusual drowsiness' as documented side effects associated with the use of Merofen. These are generally classified as rare adverse reactions.

Q: Are there any specific foods I should avoid while using Merofen?

A: Official regulatory prescribing information does not report any specific food-drug interactions or mandatory food restrictions related to the use of Merofen.

Q: Does Merofen affect blood pressure?

A: Yes, official safety documents list changes in blood pressure as a potential side effect. Hypotension (low blood pressure) and hypertension (high blood pressure) are both listed as uncommon adverse reactions associated with the medicine.

Q: Is Merofen approved for use in children?

A: Yes, official regulatory documents state that use is permitted in adults, adolescents, and pediatric patients 3 months of age and older. Safety and effectiveness have not been formally established for children younger than 3 months.

Q: What is the typical timeframe for seeing the full 'benefit' of Merofen?

A: Clinical trials evaluate outcomes like the full resolution of infection at the typical end of the treatment course (often 7 to 14 days). The full clinical response is expected to be observed within the completion of the prescribed regimen.

Q: Does Merofen affect the function of birth control pills?

A: Official regulatory documents indicate that Merofen may theoretically reduce the effectiveness of oral contraceptives that contain estrogen by altering intestinal bacteria. Official guidance notes that due to this theoretical concern, alternative or additional forms of contraception may be considered during the period of co-administration.

Q: Are there any dietary supplements that are known to interact with Merofen?

A: Official regulatory prescribing information focuses on interactions with other medicinal products (e.g., Valproate, Probenecid, Oral Anticoagulants). It generally does not document specific interaction concerns with herbal products or dietary supplements.

Q: What if I accidentally took two doses of Merofen close together?

A: Since Merofen is administered intravenously in a supervised setting, accidental overdose is unlikely. Regulatory guidance describes that if accidental overdose is suspected, discontinuation of the medicine and immediate consultation with a healthcare professional or Poison Control is the established protocol.

Q: What should I do if I notice a side effect that isn't listed in the official materials?

A: Official regulatory guidance establishes that any suspected adverse reaction, even those not listed in the official product information, must be reported to a healthcare professional, nurse, or the local regulatory drug safety agency (e.g., FDA MedWatch, MHRA Yellow Card Scheme). This is a vital part of drug monitoring.

Q: Can having a pre-existing heart condition affect how Merofen is used?

A: Official documents note that uncommon adverse reactions include hypotension, heart failure, and cardiac events. Therefore, patients with pre-existing heart conditions or conditions that require sodium restriction should be used with caution, as indicated in safety notes regarding cardiovascular events.

Q: Does Merofen require any special monitoring while being taken?

A: Yes, official guidelines require specific monitoring in certain situations, such as monitoring of coagulation metrics if the patient is receiving oral anticoagulants. Increased monitoring for central nervous system effects in patients with a history of seizures and routine monitoring of liver and kidney function tests are also common.

How should Merofen be stored and disposed of?

How to Store and Dispose of Meropenem (Merofen)

The storage and disposal of Meropenem for Injection must strictly follow official regulatory guidelines to maintain product integrity.

Storage Requirements

The unreconstituted dry powder should be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), and must be kept in its original container. The medicine must be stored out of the reach of children.

Reconstituted Solution Stability Temperature Maximum Time Limit
In 0.9% Sodium Chloride Refrigerated (4 C) 18 hours
In 5% Dextrose Refrigerated (4 C) 8 hours

Note: Reconstituted solutions should not be frozen.

Disposal

Any unused portion of the drug must be discarded. Disposal of unused or expired product should be carried out strictly according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Merofen found in:

A-Z Index: